July 29, 2009 -- Today Silicos NV, the Belgian biotech focusing on computational fragment based drug discovery, announced that it is taking several steps to increase its biological lab capabilities. First of all, Silicos has further strengthened its team to increase the capacity to screen compounds identified by Silicos as part of its internal drug discovery projects. “Our biology lab will enable Silicos to rapidly confirm the results of our computational fragment based drug discovery efforts, thereby shortening the cycle and further speed up the pace of lead discovery, which is the key of our business model”, commented Hans De Winter, Silicos"e; CSO.
Silicos is at present leasing lab space from the University of Hasselt in Belgium. As part of a move to further extending its capabilities the company will move into new accommodation on the same research park that combines offices, computer facilities and lab space.
